Introduction: Myeloid sarcoma (MS) is an extramedullary mass, consisting of myeloid blasts with or without maturation, which efface the normal tissue architecture. It occurs mainly in lymph nodes, skin and soft tissue, testis, bone, peritoneum, and gastrointestinal tract, but rarely in the pancreas. Because their clinical courses, treatments, and prognoses are quite different, it is crucially important to distinguish between MS and pancreatic cancer. Patient concerns: We herein report a rare case of acute myeloid leukemia (AML) which presented with a pancreatic mass that mimicked pancreatic cancer. Diagnosis: The diagnosis of MS was established based on immunohistochemical (IHC) analysis and bone marrow examination which revealed neoplastic cells with CD34+/CD117+. Interventions: The patient was actively treated with chemotherapy. Outcomes: After 4 cycles of chemotherapy, the lesion in pancreas was significantly reduced, and the patient is still receiving further chemotherapy. Conclusion: When we encounter a patient suspected of pancreatic cancer with blood cell abnormalities and no significant increase in carbohydrate antigen 19-9 (CA19-9), we need to be aware of the possibility of pancreatic MS. Preoperative pathological biopsy and IHC are indispensable. Misdiagnosis is common if we rely solely on imaging.
Noninvasive targeted visualization of pancreatic beta cells or islets is becoming the focus of molecular imaging application in diabetes and islet transplantation studies. In this study, we aimed to produce the beta-cell-targeted peptide for molecular imaging of islet. We used phage display libraries to screen a beta-cell-targeted peptide, LNTPLKS, which was tagged with fluorescein isothiocyanate (FITC). This peptide was validated for targeting beta-cell with in vitro and in vivo studies. Immunocytochemistry (ICC) and fluorescence-activated cell sorting (FACS) analysis were used to validate the target specificity of the peptide. FITC-LNTPLKS displayed much higher fluorescence in beta cells vs. control cells in ICC. This discrimination was consistently observed using primary rodent islet. FACS analysis showed right shift of peak point in beta cells compared to control cells. The specific bind to in situ islet was verified by in vitro experiments using rodent and human pancreatic slices. The peptide also showed high affinity of islet grafts under the renal capsule. In the insulinoma animal model, we could find FITC-LNTPLKS accumulated specifically to the tumor, thus indicating a potential clinical application of molecular imaging of insulinoma. In conclusion, LNTPLKS showed a specific probe for beta-cells, which might be further utilized in targeted imaging/monitoring beta cells and theragnosis for beta-cells-related disease (diabetes, insulinoma, etc.).
Euglycemic diabetic keto acidosis (eu-DKA) is a rare but life-threatening metabolic complication associated with sodium-glucose cotransporter-2 (SGLT-2) inhibitor therapy, especially in the setting of extreme physical stress. Due to no apparent hyperglycemia, the significant risk of delayed diagnosis or misdiagnosis exists within patients. Herein, we report a novel case of dapagliflozin-associated eu-DKA with unusual presentation. A 57-year-old female with a six-year history of type 2 diabetes mellitus (DM), for which metformin and dapagliflozin were prescribed, developed severe abdominal pain and signs of acute peritonitis without obvious hyperglycemia after distal pancreatectomy. Based on CT scan and laboratory studies, gastrointestinal tract perforation was suspected but was excluded during laparotomy. Severe metabolic acidosis and strong positive urine ketone indicated diabetic keto acidosis. The patient recovered after active therapy with an intravenous insulin infusion, antibiotics and correction of hypotension, electrolyte imbalance and acidosis. This case provides a new reference for clinicians and surgeons to be concerned with eu-DKA with severe abdominal pain as the main symptom.
Rationale: Hepatocellular carcinoma (HCC) with hepatic vein invasion poses significant treatment challenges and is associated with poor prognosis. Recent studies suggest that a combination of transarterial chemoembolization (TACE), targeted therapy, and immunotherapy may downstage advanced tumors, making surgical resection possible. Patient concerns: A 61-year-old female presented with a 3.7 × 3.1 cm hepatic mass invading the hepatic veins. A 75-year-old male exhibited a 6.7 × 5.1 cm liver tumor involving the right hepatic vein. Diagnoses: Both patients were diagnosed with advanced HCC with vascular invasion, confirmed by contrast-enhanced imaging and elevated alpha-fetoprotein (AFP) levels. Interventions: In case 1, the patient received 2 rounds of TACE and 3 cycles of lenvatinib plus tislelizumab. In case 2, the patient underwent 1 TACE session and 2 cycles of the same combination therapy. Both cases showed significant tumor shrinkage, allowing subsequent R0 surgical resection. Outcomes: Pathological evaluation following surgery revealed a major pathological response in both patients. Postoperative recovery was uneventful, and both patients remained disease-free during follow-up. Lessons: The combination of TACE, lenvatinib, and tislelizumab may offer an effective multimodal strategy for converting unresectable HCC with vascular invasion into resectable disease, potentially improving long-term outcomes.
The connection between appendiceal disease and cancers of the digestive tract has attracted widespread attention, but conclusion remain controversial. It is still unclear whether appendiceal disease has a definite causal effect on cancer. Our research aims to explore the causal relationship between appendiceal diseases and digestive system tumors. A two-sample Mendelian randomization (MR) analysis was conducted using genome-wide association study datasets to explore the causal impact of appendiceal disease on the risk of cancers. Five different MR methods were used to investigate causality. The stability, heterogeneity, and pleiotropy of MR were also assessed. The presence of appendiceal disease could reduce the incidence of rectal cancer (odds ratio = 0.588, 95% confidence interval: 0.392–0.881, P = .010, by inverse variance weighted method). There was no significant causal effect of appendiceal disease on the risk of other cancers. No horizontal pleiotropy was observed in the MR analysis, and leave-one-out analysis confirmed the stability of the results. The potential causal relationship between appendiceal disease and cancer risk was only observed with rectal cancer in populations of European ancestry. Future work will provide more robust evidence for the connection between appendiceal disease and cancers.
Rationale: Recurrent anal fistula remains a clinical challenge, especially when standard treatment fails to prevent relapse. Adjacent cystic infections may represent an underrecognized contributor to persistent or recurrent disease. Patient concerns: A patient with a long-standing history of perianal discomfort and multiple anal fistula recurrences presented with ongoing discharge and pain despite previous surgical interventions. Diagnoses: Clinical examination and intraoperative findings revealed a 2 × 2 cm infected cyst located adjacent to the recurrent anal fistula tract. Interventions: The patient underwent complete surgical excision of both the anal fistula and the adjacent infected cyst. Outcomes: Postoperative recovery was uneventful. The patient achieved sustained remission with no signs of recurrence observed during a 3-month follow-up period. Lessons: This case highlights a notable association between recurrent anal fistula and adjacent cystic infection. Cystic infection may serve as a hidden trigger for fistula reactivation and should be considered in patients with treatment-resistant perianal disease.